Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2026-04-26 @ 9:21 PM
Study NCT ID:
NCT05832827
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-04-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Sponsor:
National Cancer Center, Japan
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
NCCH2109
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |